Case Study: Inhibikase Therapeutics (NYSE:IKT) and Fennec Pharmaceuticals (NASDAQ:FENC)

Inhibikase Therapeutics ( NYSE:IKT – Get Free Report ) and Fennec Pharmaceuticals ( NASDAQ:FENC – Get Free Report ) are both small-cap medical companies, but which is the better business? We’ll compare the two businesses based on their institutional ownership strength, profitability, valuation, analyst recommendations, earnings, risk and dividends.

return

This table compares Inhibikase Therapeutics and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.

Risk and volatility

Inhibikase Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.26, indicating that its stock price is it is 74% less volatile than the S&P 500.

Analyst recommendations

This is a summary of current ratings and price targets for Inhibikase Therapeutics and Fennec Pharmaceuticals as provided by MarketBeat.

Inhibikase Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 1,150.00%. Fennec Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 167.18%. Given Inhibikase Therapeutics’ higher probable upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than Fennec Pharmaceuticals.

Institutional and privileged ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 14.7% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, big money managers and hedge funds believe the stock is poised for long-term growth.

Rating and Earnings

This table compares Inhibikase Therapeutics and Fennec Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Fennec Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics trades at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Fennec Pharmaceuticals beats Inhibikase Therapeutics in 9 of the 13 factors compared between the two stocks.

About Inhibitase Therapeutics

(Get a free report)

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops drugs for Parkinson’s disease and related disorders. The lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials for the treatment of Parkinson’s disease and the gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat chronic myelogenous leukemia in stable phase. Inhibitase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

About Fennec Pharmaceuticals

(Get a free report)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, is developing product candidates for use in the treatment of cancer in the United States. Its lead product candidate is sodium thiosulfate, which has completed a phase III clinical trial for the prevention of cisplatin-induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is headquartered in Research Triangle Park, North Carolina.

Get daily news and reviews for Inhibikase Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inhibikase Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.